IBD Patients on Biologics Achieve Normal T Cell Immunity After Full SARS-CoV-2 Vaccination
T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics.
Abstract
IBD patients on anti-TNF or anti-IL-12/IL-23 biologics develop normal Spike-reactive T cell immunity after full SARS-CoV-2 vaccination despite initial impairments.